What is the recommended intramuscular ketamine dosing regimen for treating depression, including dose, frequency, and special considerations for older adults, hepatic impairment, and cardiovascular disease?

Intramuscular Ketamine Dosing for Depression

For intramuscular ketamine in depression, administer 0.5 mg/kg as the standard dose, with a dosing range of 0.5-1.0 mg/kg based on response and tolerability. This produces antidepressant effects within 3-4 hours and typically lasts 12-25 minutes for anesthetic effects, though mood improvements persist for days to weeks 1.

Standard IM Dosing Protocol

The FDA-approved anesthetic dosing provides the foundation for off-label psychiatric use:

• Initial dose: 0.5 mg/kg IM is the most evidence-based starting point 2, 3, 4
• Dose range: 0.5-1.0 mg/kg IM has been studied, with higher doses (up to 1.0 mg/kg) showing dose-dependent dissociative effects but similar antidepressant efficacy 4
• Onset: Expect clinical effects within 3-4 minutes, with peak antidepressant response at 4-24 hours 1, 5
• Duration of effect: Single-dose antidepressant effects last 3-7 days on average 2, 3

Frequency and Treatment Course

Begin with weekly infusions for the acute phase (4-6 weeks), then transition to maintenance dosing every 2-4 weeks based on symptom recurrence 6, 7, 8:

• Acute phase: Weekly dosing for 4-6 treatments is standard practice 2, 7
• Maintenance phase: Frequency decreases from every 5 days initially to every 3-4 weeks over 5 months 8
• Long-term: Average of 18 total infusions over 12 months in real-world VA data 8
• Individualization: Dose "a little before the effect of the previous session is expected to wear off" 3

The 2022 VA/DoD guidelines emphasize that ketamine should only be used after failure of at least 2 adequate antidepressant trials 6. This is reserved for treatment-resistant depression, not first-line therapy.

Special Population Considerations

Older Adults

• Increased cardiovascular monitoring required: Patients ≥50 years show greater systolic and diastolic blood pressure elevations (mean increases of 7.4/6.0 mmHg at 30-40 minutes) 9
• No dose adjustment specified in available evidence, but start at 0.5 mg/kg with enhanced vital sign monitoring
• Monitor blood pressure every 10 minutes during infusion and for 30 minutes post-infusion 9

Cardiovascular Disease

• Hypertensive patients show greater blood pressure increases but paradoxically less pulse elevation 9
• Ketamine increases blood pressure, heart rate, and cardiac output through indirect sympathomimetic activity 1
• Blood pressure peaks 10-50% above baseline within minutes, returning to baseline within 15 minutes in most cases 1
• Contraindicated in patients where significant blood pressure elevation poses serious risk (per FDA labeling) 1
• Consider lower starting dose (0.5 mg/kg) and ensure continuous cardiovascular monitoring

Hepatic Impairment

• No specific dosing adjustments provided in FDA labeling or psychiatric literature 1
• Ketamine is metabolized primarily by CYP2B6 and CYP3A4 1
• Use clinical judgment: start at 0.5 mg/kg with close monitoring for prolonged effects or adverse events
• Critical gap in evidence: hepatic dosing requires further study

Critical Safety Considerations

Administer only in settings with:

• Physician experienced in general anesthetics and airway management present 1
• Continuous vital sign monitoring (every 10 minutes during and 30 minutes post-infusion) 1, 9
• Emergency airway equipment immediately available 1
• 2-hour post-treatment monitoring period (similar to esketamine REMS requirements) 6

Key Adverse Effects to Monitor

• Dissociative symptoms: Dose-dependent; patients with dissociative symptoms show greater blood pressure increases 9
• Cardiovascular: Transient hypertension and tachycardia peak at 30-40 minutes 9
• Genitourinary pain: With chronic use, consider cessation if persistent genitourinary symptoms develop 1
• Abuse potential: Schedule III controlled substance; risk increases with history of substance use 1

Common Pitfalls to Avoid

1. Do NOT use as first-line treatment: Reserve for patients who have failed ≥2 adequate antidepressant trials 6
2. Do NOT administer without proper monitoring: Respiratory depression and enhanced vasopressor response can occur 1
3. Do NOT ignore cardiovascular risk factors: Older age, hypertension, and larger doses predict greater cardiovascular effects 9
4. Do NOT expect sustained monotherapy effects: Benefits typically require ongoing maintenance dosing 6, 8

Evidence Quality and Nuances

The 2022 VA/DoD guidelines 6 represent the highest-quality, most recent guidance, marking a significant shift from the 2016 recommendation against ketamine use outside research. However, most evidence is for IV ketamine at 0.5 mg/kg over 40 minutes 2. IM ketamine data is more limited but shows similar efficacy 5, 3, 7, 4.

Real-world VA data shows modest response rates: only 26% achieved 50% PHQ-9 improvement and 15% achieved remission at 6 weeks 8. However, those who respond maintain improvements for at least 6 months with decreasing infusion frequency 8.

The dose-response relationship is complex: while 1.0 mg/kg IM produces more dissociative effects than 0.5 mg/kg, antidepressant efficacy appears similar 4. Some patients may respond to doses as low as 0.1 mg/kg, while others require up to 0.75 mg/kg 3.